Sign In
Buy CNTA
$39.85
-0.0500 (-0.125%)
At Close: Jun 03, 2026
Centessa Pharmaceuticals Teases ORX750 Phase II Update, Registrational Study Start at Conference
02:02am, Tuesday, 10'th Mar 2026
Centessa Pharmaceuticals (NASDAQ: CNTA) used remarks at a healthcare conference to highlight recent progress in its orexin agonist program and outline near-term priorities that include a Phase II upda
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
03:03am, Thursday, 05'th Mar 2026
Tokyo, Japan and Cambridge, UK, 5 March 2026 - Nxera Pharma Co. , Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development m
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%
10:09am, Monday, 23'rd Feb 2026
Commodore Capital sold 1,850,000 shares of Centessa in the fourth quarter; the estimated trade value was $46.86 million. Meanwhile, the quarter-end position value decreased by $44.10 million, reflecti
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition
05:03pm, Thursday, 19'th Feb 2026
Connecticut-based Braidwell initiated a position of 2,188,320 Centessa shares in the fourth quarter. The quarter-end value of the position increased by $54.73 million, reflecting the new stake.
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
03:45am, Thursday, 12'th Feb 2026
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development mil
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 03'rd Feb 2026
BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines
This Fund Locked In Gains With a $14.5 Million Biotech Exit Amid a Staggering Stock Rally
07:09pm, Sunday, 01'st Feb 2026
Tanager Wealth Management exited its entire CNTA position, reducing holdings by 598,044 shares in the fourth quarter. As a result, the quarter-end position value decreased by $14.50 million, reflectin
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of “Moderate Buy” from Analysts
02:44am, Sunday, 01'st Feb 2026
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen analysts that are currently covering the firm, Marketbeat R
Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder Antidepressive effects and enhanced wakefulness were observe
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
03:09am, Tuesday, 13'th Jan 2026
Tokyo, Japan and Cambridge, UK, 13 January 2026 - Nxera Pharma Co. , Ltd. ("Nxera" or "the Company"; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associate
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of “Moderate Buy” by Brokerages
01:30am, Wednesday, 07'th Jan 2026
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report) has received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Mark
Critical Review: Centessa Pharmaceuticals (NASDAQ:CNTA) & Universe Pharmaceuticals (NASDAQ:UPC)
01:32am, Monday, 22'nd Dec 2025
Centessa Pharmaceuticals (NASDAQ: CNTA - Get Free Report) and Universe Pharmaceuticals (NASDAQ: UPC - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Recommendation of “Buy” from Analysts
01:16am, Saturday, 13'th Dec 2025
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA - Get Free Report) has been assigned an average recommendation of "Buy" from the thirteen analysts that are currently covering the firm, Market
Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, appointed Chief Executive Officer and member of the Board of Directors Mario Alberto Accardi PhD, President and founder o
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company
01:48pm, Saturday, 29'th Nov 2025
San Francisco-based 5AM Venture Management sold 150,000 CNTA shares in the third quarter. Despite the sale, the stock's sharp rally last quarter led the fund's net position value in CNTA to increase b
